Activation of the myeloid checkpoint inhibitor LILRB3 (ILT5) elicits profound immununomodulation

Added 38 days ago (06.06.2020)
Authors: Yeboah, M., Papagregoriou, C., Jones, D. C., Chan, H. T. C., Hu, G., McPartlan, J. S., Schiott, T., Mattson, U., Mockridge, C. I., Tornberg, U.-C., Hambe, B., Ljungars, A., Mattsson, M., Tews, I., Thirdborough, S. M., Trowsdale, J., Frendeus, B., Chen, J., Cragg, M. S., Roghanian, A.
Source: bioRxiv
Read article